ImmunoGen, Inc.
IMGN · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $1,258,010 | $1,529,611 | $1,136,187 | $757,869 |
| - Cash | $275,138 | $275,138 | $293,856 | $176,225 |
| + Debt | $15,244 | $15,244 | $23,890 | $26,847 |
| Enterprise Value | $998,116 | $1,269,717 | $866,221 | $608,491 |
| Revenue | $108,782 | $69,856 | $132,299 | $82,271 |
| % Growth | 55.7% | -47.2% | 60.8% | – |
| Gross Profit | $108,606 | $69,856 | $17,707 | -$32,251 |
| % Margin | 99.8% | 100% | 13.4% | -39.2% |
| EBITDA | -$215,763 | -$124,187 | -$19,683 | -$65,726 |
| % Margin | -198.3% | -177.8% | -14.9% | -79.9% |
| Net Income | -$222,929 | -$139,303 | -$66,683 | -$122,093 |
| % Margin | -204.9% | -199.4% | -50.4% | -148.4% |
| EPS Diluted | -0.879 | -1.081 | -0.38 | -0.82 |
| % Growth | 18.7% | -184.6% | 53.7% | – |
| Operating Cash Flow | -$229,802 | -$229,802 | -$78,620 | -$88,367 |
| Capital Expenditures | -$1,364 | -$1,364 | -$917 | -$2,845 |
| Free Cash Flow | -$231,166 | -$231,166 | -$79,537 | -$91,212 |